ClinicalTrials.gg

Pulmonary Arterial Hypertension clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 701 studies for Pulmonary Arterial Hypertension across more than 10 countries. 142 are recruiting or about to start. 630 of them are mainly about Pulmonary Arterial Hypertension (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 2,098 studies for Pulmonary Arterial Hypertension. How that becomes 699 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Pulmonary Arterial Hypertension, and those it files under no condition that list Pulmonary Arterial Hypertensionthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 2,098Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −18List Pulmonary Arterial Hypertension as a condition, but the registry did not file them under itMost often written as “Idiopathic Pulmonary Arterial Hypertension” (13), “Secondary Pulmonary Arterial Hypertension” (2), and “Heritable Pulmonary Arterial Hypertension” (2). The registry filed them under other conditions only, most often Familial Primary Pulmonary Hypertension (14) and Hypertension, Pulmonary (2).
  3. −1,381Match it another way125 name it in the title, 1 in a keyword, and 1,255 by a synonym or other text the search reads.
  4. 699The count on this page6 of them list Pulmonary Arterial Hypertension in their own words; the registry filed them under no condition.

Status

Completed
341
Recruiting
90
Terminated
84
Status unknown
61
Not yet recruiting
47
Withdrawn
37

Phase

Phase 2
140
Phase 3
113
Phase 1
86
Phase 4
64
Early Phase 1
5

Where

United States
313
Germany
119
France
103
United Kingdom
98
Canada
85
Spain
77

Who develops what

Add Pulmonary Arterial Hypertension to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 15 programs from 14 companies, 14 with this as their studies’ main aim; 5 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Bial - Portela C, Humanis Saglık Anonim Sirketi and Insmed here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
TadalafilEarlier only
Evidence
  • NCT04483115 · Vigonvita Life Sciences · Phase 2 · comparator · “Tadalafil” · registered Jul 2020
  • NCT03904693 · Johnson & Johnson · Phase 3 · comparator · “Tadalafil 40 mg” · registered Apr 2019
  • NCT02891850 · Bayer · Phase 4 · comparator · “Tadalafil” · registered Aug 2016
  • NCT02558231 · Johnson & Johnson · Phase 3 · background · “Tadalafil” · registered Sep 2015
  • NCT00617305 · Gilead Sciences · Phase 4 · background · “Tadalafil” · registered Feb 2008
Eli Lilly and Company67% of its industry studiesUS: off-patent, 31 generics marketedEU: off-patent, 2 generics authorized00 studies
sildenafilEarlier only
Evidence
  • NCT02891850 · Bayer · Phase 4 · comparator · “Sildenafil” · registered Aug 2016
  • NCT00617305 · Gilead Sciences · Phase 4 · background · “Sildenafil” · registered Feb 2008
  • NCT00433329 · Johnson & Johnson · Phase 4 · background · “Sildenafil” · registered Feb 2007
Viatris Inc.64% of its industry studiesUS: off-patent, 35 generics marketedEU: off-patent, 6 generics authorized00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
treprostinil hexadecyl ester☆ Track2 live phase-3 studies: NCT05649748, NCT07481981Insmed Incorporated
TacrolimusApproved: US · EU☆ Track1 live phase-3 study: NCT07612657vivus
sotaterceptApproved: EU 2024☆ Track1 live phase-3 study: NCT07218029Merck & Co., Inc
IKT-001☆ Track2 live phase-3 studies: NCT07365332, NCT07632898Inhibikase Therapeutics
treprostinilApproved: US · EU 2020☆ Track1 live phase-3 study: NCT03992755Liquidia Technologies, Inc.

The 5 in phase 3 with the nearest primary completion, of 15 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Dec 2026 est.treprostinil hexadecyl ester · Insmed Incorporated · Phase 3 main aimNCT05649748 An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) — primary endpoint: Number of Participants Who Experience at Least one Treatment Emergent Adverse Event (TEAE) and TEAEs by Severity · 91 enrolled
  • Mar 2027 est.ROC-101 · AllRock Bio, Inc. · Phase 2 main aimNCT07175038 A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY) — primary endpoint: Change in Pulmonary Vascular Resistance (PVR) from Baseline versus at 24 weeks · 40 enrolled
  • May 2027 est.treprostinil · Liquidia Technologies, Inc. · Phase 4 main aimNCT07759804 A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag — primary endpoint: Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) · 20 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Pulmonary Arterial Hypertension studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Endothelin receptor antagonists 5 open · PDE5 inhibitors 3 open · Tyrosine kinase inhibitors (TKIs) 1 open · Diuretics 1 open · Bronchodilators 1 open

Coming up

46studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger. 18 (20%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 11 (12%) take healthy volunteers.

Recruiting studies that take each age, of 90
AgeWomenMen
1016 (18%)16 (18%)
1886 (96%)85 (94%)
3083 (92%)82 (91%)
4083 (92%)82 (91%)
5082 (91%)82 (91%)
6581 (90%)81 (90%)
7577 (86%)77 (86%)
8558 (64%)58 (64%)

Across all 701 studies, recruiting or not: 33% stop at 75 or younger and 15% at 65; 19% take children; 1% are for women only and 1% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Pulmonary Arterial Hypertension studies take

Of 51 phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 44 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 19 mo2–22 · 45 studies5 mo2–17 · 34 studies—
Phase 244 mo26–65 · 51 studies31 mo19–48 · 28 studies—
Phase 350 mo31–83 · 49 studies50 mo31–83 · 43 studies—
Interventional, no phase42 mo18–71 · 65 studies—44 mo18–63 · 60 studies
Observational58 mo30–93 · 85 studies—60 mo31–… · 64 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 701. Browse all 701 → or search them.